Drs Abraham and Feuerstadt share recent data with emerging live biotherapeutic products, SER-109, CP101, and VE303, for treatment of recurrent C difficile infection (rCDI).

C diff patients live in fear of a recurrence, says gastroenterologist Paul Feuerstadt, MD. RBX2660 has entered the FDA pipeline and looks to end this vicious cycle.

.@AARP highlights #CDiff's potential to cause debilitating symptoms in patients and notes the work of @Rebiotix and @SeresTX to develop novel #microbiome therapeutics to treat this recurrent and often deadly GI infection. Read more: https://t.co/hmoseHtYhR— MTIG (@MTIG_News) September 27, 2022

Patients receiving healthcare are at higher risk of acquiring healthcare-associated infections, which cause a significant number of illnesses and deaths. Most pathogens responsible for these infections are highly resistant to multiple antibiotics, prompting the need for discovery of new therapeutics …

Our findings demonstrated that TcdA induced the upregulation of the P2X7 receptor, which promoted enteric neuron loss, S100B synthesis, tissue damage, inflammation, and cell death in the mouse ileum. These findings contribute to the future directions in understanding the mechanism involved in intest …

Patients receiving healthcare are at higher risk of acquiring healthcare-associated infections, which cause a significant number of illnesses and deaths. Most pathogens responsible for these infections are highly resistant to multiple antibiotics, prompting the need for discovery of new therapeutics …

The results of the present study highlighted that CCM and CAP can modulate the inflammatory response and apoptotic effects induced by Tox-S from different clinical C. difficile strains in vitro. Further studies are required to accurately explore the anti-toxin activity of natural components, and the …

Right around the beginning of the year, we got a close-up look at what happens after a boom ripples through biotech. The crash of life sciences stocks in Q1 was heard around the world. In the months since, we've seen the natural Darwinian down cycle take effect. Reverse mergers made

Clostridioides difficile infection (CDI) is classified as an urgent health threat by the Centers for Disease Control and Prevention (CDC), and affects nearly 500,000 Americans annually. Approximately 20-25% of patients with a primary infection experience a recurrence, and …

The Vaccines and Related Biological Products Advisory Committee's (VRBPAC) positive vote follows the committee’s review of the data from the biologics license application (BLA) for RBX2660.

Dublin, Sept. 19, 2022 (GLOBE NEWSWIRE) -- The "Microbiome Therapeutics Market Size, Share & Trends Analysis Report by Type (FMT, Microbiome Drugs),...

The broad and potent in vitro antibacterial activity and lower risk of drug resistance suggested that OPS-2071 may be useful for enteric infections caused by major pathogens including quinolone-resistant Campylobacter.

Recursion has initiated two additional clinical trials including its first in-house generated new chemical entity to enter the clinic.

/PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced the...

By Joe Hoppe Destiny Pharma PLC said Wednesday that the European Medicines Agency has given positive feedback on its proposed Phase 3 development program for...

Interesting new findings on the differences in nutrient use by our gut bacteria. Are we ready for personalized dietary advice based on microbiome preferences rather than food pyramids?https://t.co/qUH72R0ymM— GutMicrobiota Health (@GMFHx) September 8, 2022

A new study suggests that the natural compound hydroquinine may be effective in fighting multidrug-resistant bacteria, including some that cause hospital infections.

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for SER-109 for the prevention of recurrent C. difficile infection (rCDI).

The European Medicines Agency has said a single, final-stage study will be enough to make a marketing authorisation application

Join Acurx Pharmaceuticals' Executive Chairman, Robert Deluccia today at 12:00 PM as he discusses the Company's development of Ibezapolstat for the potential treatment of #CDiff. https://t.co/I6ffQbrRiC— Antimicrobials Working Group (@AWG_News) September 7, 2022

.@gianluca1aniro: Alternatives of FMT include defined microbial consortia such as RBX2660 and SER-109 that have shown durable engraftment and good safety profile @esnm_eu #GMFHCoverage pic.twitter.com/I2zOzscgLB— GutMicrobiota Health (@GMFHx) September 6, 2022

By Joe Hoppe Destiny Pharma PLC said Wednesday that the European Medicines Agency has given positive feedback on its proposed Phase 3 development program for...

Seres Therapeutics Announces Completion of Rolling Bla Submission to FDA for Investigational Microbiome Therapeutic Ser-109 for Recurrent C. Difficile Infection.Seres Therapeutics Inc - Anticipated Product Launch in First Half of 2023.

The European Medicines Agency has said a single, final-stage study will be enough to make a marketing authorisation application

* Immuron approved to commence clinical study in c.difficile infection (cdi)

The FDA's #VRBPAC will meet on September 22 to review data supporting the biologics license application (BLA) for @Rebiotix's RBX2660, a microbiota-based live biotherapeutic studied for its potential to reduce recurrent #CDiff after antibiotic treatment. https://t.co/GClrIVBPna— MTIG (@MTIG_News) August 22, 2022

Four novel vaccine candidates developed by a University of Guelph chemist have been recently recognized by the World Health Organization (WHO) for potential use in treating what medical experts call a…

In a recent report, the World Health Organization recognized four vaccine candidates developed by U of G prof Mario Monteiro and his research team

An FDA advisory committee will meet on September 22, 2022 to decide whether to approve a biologics license application (BLA) for Ferring’s recurrent C difficile biotherapeutic, RBX2660.